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ABSTRACT
Cervical dystonia (CD) usually presents a complex pattern of head/neck movements accompanied by tremor, myoclonic jerks 
and a wide spectrum of non-motor disturbances such as pain, depression, anxiety, and sleep problems. This is the most challen-
ging indication for botulinum neurotoxin (BoNT) treatment. It can offer significant improvement, but it can be difficult after the 
first injection. Thorough examination and identification of the proper CD pattern, the identification of the muscles responsible, 
and adjusting doses given precisely under ultrasound and/or electromyographic guidance seem to be the key success modifiers. 
Nevertheless, this is a lifelong treatment and should be planned and conducted carefully to avoid failures and drop outs. The 
aim of this paper was to examine the current concepts in terms of anatomy, physiology and CD patterns (Col-Cap concept) as 
well as the proper dosages and any possible obstacles impeding successful treatment. 
Key words: botulinum neurotoxin, cervical dystonia, electromyography, ultrasonography, deep brain stimulation
(Neurol Neurochir Pol 2021; 55 (2): 125–132)
Introduction and aim
Cervical dystonia (CD) remains the most challenging 
indication for botulinum neurotoxin (BoNT) treatment. 
However effective, the improvement is usually suboptimal 
and unsatisfactory for many patients. In recent years, the 
approach to this treatment has evolved, with new concepts 
emerging regarding muscle involvement in the clinical pat-
terns of CD (the Col-Cap concept) [1]. Unfortunately, for 
this new classification we do not have any proper scales to 
rate the improvement. Non-motor symptoms accompanying 
motor presentation may not respond to BoNT and can result 
in worse self-assessment of patients despite the head/neck 
correction. Guided injections (electromyography EMG, and 
ultrasound US), currently considered to be the standard ap-
proach, lack proof of their superiority over treatment based 
on anatomical landmarks and clinical judgment only. We 
still do not know the optimal dose per muscle. The growing 
number of toxins with different pharmacological properties 
and different dosing regimens (BoNT/A as onabotulinum-
toxinA: ONA-BoNT/A, abobotulinumtoxinA: ABO-BoNT/A 
and incobotulinumtoxinA: INCO-BoNT/A and BoNT/B as 
rimabotulinumtoxinB: RIMA-BoNT/B) renders this problem 
even more complicated. Refractory cases should be assessed 
carefully for pseudoresistance, and deep brain stimulation 
(DBS) may be an alternative treatment [2].
However, the American Academy of Neurology Task 
Force has placed ABO-BoNT/A and RIMA-BoNT/B at level 
A, and ONA- and INCO-BoNT/A at level B [3]. The recently 
published report of the Cochrane Library stated: “We are 
moderately certain in the evidence that a single BONT/A 
treatment session resulted in a clinically relevant reduction 
of CD specific impairment, and pain, and highly certain that 
it is well tolerated, compared with placebo. There are no data 
from RCTs evaluating the effectiveness and safety of repeated 
BtA injection cycles. There is no evidence from RCTs to allow 
us to draw definitive conclusions on the optimal treatment 
intervals and doses, the usefulness of guidance techniques 
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for injection, the impact on quality of life, or the duration of 
treatment effect.“ [4]
The aim of this paper was to revisit the treatment concepts 
of CD in terms of recently published papers, and look for 
unresolved questions to be addressed in future studies.
History and clinical examination
Over the last 30 years, BoNT has become established as 
the therapy of choice for CD. Early therapeutic work on CD 
considered it to be synonymous with spasmodic torticollis, and 
therapeutic recommendations corresponded mainly to the ro-
tatory form. As a consequence, the sternocleidomastoid muscle 
and the contralateral splenius capitis muscle were injected. The 
good results of this early work led to approval studies being 
conducted, and then to approval being granted for the relevant 
muscles in rotatory spasmodic torticollis. Injection at that time 
was done according to clinical considerations, landmarks, and 
occasionally under EMG guidance [5].
In the last decade however, new considerations have be-
come relevant: on the one hand more muscles are now being 
injected, and on the other hand a good many novel sub-forms 
have been identified. Another step forward concerns major 
progress in the use of US technology. One problematical as-
pect here is how to prove that with differentiating sub-forms 
and with the help of extensive diagnostic tools, results would 
be much better. Nonetheless, it is overall advantageous when 
recent developments are kept in mind for the purposes of 
medical training and, even more so, for improving on thera-
peutic attempts [1, 6, 7].
Since the introduction of a new classification system and 
of new techniques, a number of very useful modifications and 
extensions have been established in recent years for taking 
the medical history as well as for the clinical examination 
[1, 6, 7]. The patient is interviewed as to their initial symptoms, 
the course of their development, ensuing symptoms (such as 
pain) and sensory tricks. Keeping the Col-Cap classification 
in mind, the primary relevant information on CD is obtained 
as soon as the patient enters the examination room and sits 
opposite the physician during anamnesis. Importantly, the 
patient should be seated parallel to the physician (not, as is 
too often the case, at an oblique angle) and should remove 
necklaces, scarves or turtle neck pullovers so that the posi-
tion of the head and neck can be fully assessed. This usually 
suffices to evaluate the relevant head mispositioning and any 
possible sensory tricks.
At examination, a seat without a backrest is best used so 
that the patient does not have the opportunity to lean back, 
and also so that the physician can walk completely around 
him or her, or alternatively the patient can turn around while 
seated [8]. The patient should be asked to close his or her eyes 
so as to avoid possible positional correction through visual 
control and should be prevented from returning the head to 
the neutral position. In case of rotation of the trunk or raising 
one shoulder, a third person can best fixate that shoulder. The 
patient is then requested to demonstrate a sensory trick (geste 
antagoniste). The function and its possible reduction can be 
examined by having the patient rotate their head in the differ-
ent planes of movement: flexing it ventrally and laterally, and 
extending it dorsally. Subsequently, the patient is examined 
while standing and while walking so as to judge movement 
and the influence of walking behaviour on the position of the 
head and possible compensatory mechanisms. This is followed 
by a clinical examination of the head position and the planes 
of movement, the muscle tonus and strength [8].
In cases of tremor-predominating types (e.g. ‘no-no,’) 
careful observation of tremor disappearance when turning the 
head to one side may help to establish the dominant direction 
of the dystonia. On the other hand, enhancement of tremor 
may suggest the activity of compensatory muscles.
After this initial examination, one must classify properly 
the subtype(s) of CD [1, 6, 7].  It is very rare that movements 
are found at one level alone; a combination of several forms is 
more common. It is frequently quite difficult to judge which 
movements are the paramount ones, which are the resultant 
compensatory ones, and which muscles play an agonistic or 
antagonistic role in the different subtypes [7]. Therefore, our 
personal practice is to limit ourselves to the lead pattern and 
the relevant muscles. In subsequent treatments, doses and 
muscle selection will be adjusted. The muscles to be injected 
are selected depending on the type of CD under examination. 
In complex cases, electromyography (EMG) is also useful for 
better differentiation between active and non-active muscles. 
This is especially true for muscles without a phasic component, 
but EMG may be useful in identifying muscles involved in 
tremor, where compensatory contraction is less likely to be 
a confounder. The EMG examination is likewise best done 
under ultrasound guidance.
Anatomy and classification
While in previous decades we selected muscles for injec-
tion based on the form of CD, today we pay more attention 
to anatomical considerations. While earlier we made use of 
a deductive (top-down) methodology, today we apply rather 
an inductive (bottom-up) or individual approach [6, 7]. Muscle 
origins, their insertions, and their functions, are the basics 
required for understanding CD patterns. According to the 
so called ‘Col-Cap concept’, three dimensions of movement 
in two levels can be distinguished [1, 6]. From a functional 
point of view, there are two levels in which we differentiate 
the upper level between the skull and C2 and the lower one 
between C2 and C7, with the C2 vertebra regarded as a kind of 
fixed point. Dystonic activity of muscles with C2 (and above) 
and skull insertions form the so-called ‘caput’ and those with 
insertions below C2 and vertebral (or other) insertions are 
responsible for the so-called ‘collis’ subtypes (Fig. 1) In ad-
dition to the classical definitions of laterocollis, retrocollis, 
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Torticaput (n = 150) was combined in 46% with laterocaput, 
and in 20.7% with retrocaput. Furthermore it was combined 
in 18.7% with torticollis, and 12.7% with laterocollis. Latero-
caput, the second most common primary pattern (n = 51), 
was combined mainly with torticaput (45.1%), laterocollis 
(33.3%), retrocaput (23.5%), and antecollis (15.7%). Latero-
collis (n = 30) was accompanied by laterocaput in 67.7%, 
torticaput in 46.7%, and in 16.7% by antecollis or retrocaput. 
The highest positive correlations were found for retrocaput 
with retrocollis [10].
The mean number of injected muscles in all patients was 
4.2 (SD 1.6). In patients with torticaput, it was 4.4 (SD 1.6), 
in laterocaput 4.4 (SD 1.4), in laterocollis 4.0 (SD 1.4), and in 
torticollis (n = 27) 4.2 (SD 1.8) [9].
BoNT/A dose per muscle and per session
In the majority of studies, the doses per muscle or the 
total dose per session have been established arbitrarily. The 
recommendations published to date are not based on relevant 
studies finding the proper dose, but on the clinical experience 
of experts and pre-established doses used in the pivotal clinical 
studies and then adopted in summary product characteristics 
(SPC). According to the SPCs, it is recommended that for 
ONA-BoNT/A, a maximal dose of 200U should be admin-
istered at first and should not exceed 300 U in the following 
treatment sessions [12]. There is a similar recommendation 
for INCO-BoNT/A [13]; for ABO- BoNT/A, the recom-
mended starting dose is 500 U with a subsequent possibility 
to increase up to 1,000 U if appropriate and if no dysphagia 
has been observed at the lower dose [14]. The US Food and 
Drug Administration recommends doses up to 400 U for both 
ONA- and INCO-BoNT/A, 1,000 U for ABO-BoNT/A, and 
10,000 U for RIMA-BoNT/B [15].
In a group of 305 patients representing real life treat-
ment with stable and effective doses in the previous ses-
sions, 154 patients received ONA-BoNT/A, 53 patients 
INCO-BoNT/A, and 98 patients ABO-BoNT/A. The mean 
total doses for a treatment session with ONA-, INCO- and 
ABO-BoNT/A were 159.5 U (SD = 62.4), 173.4 U (SD = 99.2), 
and 652.5 U (SD = 285.5) respectively. The doses injected 
into each muscle in the ONA- or INCO-BoNT/A groups were 
between 19.7 U and 49.2 U. The highest dose was injected 
into the splenius capitis, 49.2 ± 26.0 U, with the highest 
total dose per session being 130 U. The doses in the ABO- 
-BoNT/A group were between 75.4 and 139.6 U per muscle, 
with the highest dose injected into the splenius capitis: 
139.6 ± 80.7 U [16]. These real-life doses were lower than 
those recommended by experts [17, 18]. We assume that the 
use of US guidance in our group [16] may be an advantage, 
and that more precise injections may result in lower doses 
being used subsequently, although this is only an indirect 
supposition. Keeping doses at effective, but also not too high, 
levels is recommended because doses that are too high may 
Figure 1. Anatomical basis of Col-Cap concept: Two levels of mo-
vement with C2 as a fixed point (modified as per Jost W. Atlas of 
Botulinum Toxin Injection‚ 3rd edition, KVM Verlag, Berlin, 2019)
anterocollis, and rotatory torticollis, we must add laterocaput, 
retrocaput, antecaput, and rotatory torticaput. Furthermore, 
three different forms of shift, as a combination of simple 
patterns, should be added. Lateral shift is a combination of 
laterocollis to one side and laterocaput to the opposite side; 
anterior shift is a combination of anterocollis and retrocaput; 
and retroshift is a combination of retrocollis and antecaput 
[6, 7]. Data regarding this extended list of patterns can be 
found in our previous papers [5, 6].
It is not yet clear whether certain muscles constitute 
a single functional unit, or rather whether there are complete 
muscle chains. We do now know that some muscles are pref-
erentially involved and that certain combinations present to-
gether more frequently [9, 10]. In a recent study of 306 patients, 
splenius capitis was the most commonly involved muscle 
(83%), followed by sternocleidomastoid (79.1%) and trapezius 
(58.5%). This was followed by levator scapulae, semispinalis 
capitis, and obliquus capitis inferior in 38.2%, 48.7% and 35.3% 
respectively. In torticaput, three muscles were injected in over 
half of the patients, splenius capitis (88%), sternocleidomatoid 
(84%), and trapezius (60.7%) [9].
The most common primary form was torticaput (49%), fol-
lowed by laterocaput (16.7%). Within this group, 16.3% of the 
patients had only one subtype of CD, 40.2% had two subtypes, 
24.5% had three subtypes, and 19% had four or more subtypes [10]. 
In the whole group, only 9.8% presented with laterocollis, and 
8.8% with torticollis. All other subforms made up less than 5%. 
The frequency of head tremor was 57.6%, and torticaput was the 
most common dystonic subtype associated with tremor [11]. 
Many simple subtypes formed a complex pattern. 
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result in the formation of neutralising antibodies in long-
term treatment [19].
Injection and the use of EMG and US
Since the very beginning of BoNT therapy, injections 
have been conducted taking into consideration anatomical 
landmarks. The use of EMG has become a well established 
tool. It improves the precision of the injection, especially the 
accuracy of needle placement within active muscles [5, 20]. 
Thus, it may also improve safety and efficacy. It allows iden-
tification of the target and the most active muscles, but is 
unable to differentiate between ‘dystonic’ and ‘non-dystonic’ 
(compensatory) muscles. 
At present US still competes with EMG [5]. Strictly speak-
ing, there is no actual competition for the better position, but 
rather a debate on which gives better training for medical per-
sonnel. US outlines the anatomical structures more exactly [21], 
while EMG portrays function better. The two methods are thus 
not substitutes for one another, but rather complement each 
other (visibility and function) [5, 22]. 
In addition, US, in improving the precision of injection, 
thereby improves safety and possibly efficacy. Furthermore, 
it allows for standardisation, because we can record in detail 
just which muscles we are injecting with which doses. During 
training, we can adequately portray the muscles involved, as 
well as their relationships to other muscles and structures such 
as nerves, vessels and bones. We have learned that muscles can 
often differ between individuals, and that individual muscles 
can be very thin (e.g. trapezius), meaning that a precise injec-
tion can only be guaranteed with the help of US. This is the 
only way to offer assurance that BoNT is applied precisely 
where we intend it [21–23]. 
We are more successful now in pinpointing injections, and in 
reaching muscles which we could not target earlier [22–25]. As 
a case in point, we should mention OCI (obliquus capitis inferior) 
which plays an essential role in the most frequent form of CD 
and which used to be only rarely targeted for injection [22, 26]. 
In summary, we have found that US is indispensable and 
that EMG is useful in complicated cases and in combination 
with US [22]. 
Nevertheless, an unresolved problem remains regarding 
the clinical superiority of guided injections versus blinded 
ones, as we do not have comparative studies showing better 
results achieved by guided injections. However, in cadaver 
studies, the accuracy of needle placement was 100% with US 
vs. 79.2% without US for superficial muscles and 95.8% vs. 
54.2% for deep muscles (with statistical significance) [25]. 
This should translate into a better clinical effect, but we need 
further studies performed on living patients.
One study assessed the impact of monitoring techniques 
such as US and/or CT in a small group of eight patients requir-
ing injections in deep cervical muscles (obliquus capitis infe-
rior, longus colli, obliquus capitis superior, scalenus anterior 
and scalenus posterior). The Tsui Scale confirmed a significant 
improvement occurring within four weeks (11.75 vs. 1.50) 
and on the TWSTRS (Toronto Western Spasmodic Torticollis 
Rating Scale) in each of the subscales (20.0 vs. 5.25, 20.0 vs. 
7.0, and 13.1 vs. 6.5) [27].
Non-motor symptoms and rating scales
In addition to abnormal head postures, many patients pres-
ent with so-called non-motor symptoms (NMS) [28–30]. It is 
a matter of debate whether these are direct or indirect symp-
toms of the disease. Non-motor symptoms have been reported 
in several studies: lack of self-confidence due to stigmatisation 
(61.8%), sleep problems (59.8%), and fatigue (51%) [28]. In 
the study by Sławek et al., the authors reported depression 
in 47.5% of patients, and this was the major determinant of 
poor quality of life. Furthermore, after BoNT/A injection, the 
size effect for motor improvement in TWSTRS was favour-
able (1.1 SD 0.6) and much lower (0.5 SD 0.7) for depression 
(Montgomery-Asberg Depression Rating Scale) [31]. This 
might suggest that abnormal head posture and stigmatisation 
have no indirect impact and that depression is part of the 
spectrum of symptoms of CD itself. This was further proved 
by Berardelli et al. in 2015 when the authors demonstrated 
that after five years the successful treatment of motor problems 
(a statistically significant reduction in TWSTRS from 33.4 
± 11.1 to 26.9 ± 10.9) did not correlate with an improvement 
of neuropsychiatric symptoms (65% vs. 64%) [32]. In a recent 
publication by Klingelhöfer et al., pain, insomnia and stigma 
were most prevalent, and emotional well-being and pain had 
a major impact on quality of life. Most NMS, with the excep-
tion of pain, stigma and daily activity, did not correlate with 
motor severity [29]. 
Self-awareness of motor dysfunction is higher in CD 
than in other patients with dyskinesias (e.g Parkinson’s and 
Huntington’s Diseases) and groups have been matched for 
depression, which may explain the poor impact of CD on 
emotional well-being [33].
Stamelou et al. concluded that NMS are not mere epiphe-
nomena of dystonia and demand the same level of attention as 
motor ones. They should be considered in future pathophysi-
ological models of dystonia [34].
Therefore, in conclusion we have to assess improvement 
based both on motor and NMS. Unfortunately, evaluation us-
ing the old version of TWSTRS and Tsui score did not consider 
NMS [35]. They are however taken into consideration in the 
new version of the TWSTRS, but this does not include the 
Col-Cap classification. Basically, the decision has to be made 
as to whether all symptoms should be considered, or only those 
symptoms which are improved by specific therapeutic mea-
sures. Any future rating scale must satisfy these requirements. 
Lack of improvement of NMS despite good head position 
after BoNT injection may be responsible for treatment failures 
and drop outs in long-term treatment.
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Treatment failures
Supnet et al. noted long-term treatment discontinuation 
in 36.2% of a relatively large group of patients. Fifty seven 
percent of them described suboptimal effect, high costs and 
long distance to the treatment centre. Eight per cent reported 
the lack of any improvement, only 47% had regular treatment 
sessions every 12 weeks, and the results were statistically 
worse in males [36]. Treatment failures include a long list 
of possible causes from the misidentification of proper CD 
pattern, muscle profiles, doses per muscle, side effects, and 
technical issues (too deep injections, too short needles used, 
no treatment guidance like EMG or US) to the formation 
of neutralising antibodies. Also, secondary or symptomatic 
dystonias as well as pseudodystonias have to be considered if 
the treatment is not effective. Pseudodystonias were revisited 
by Berlot et al. in 2019 and new disorders e.g. fibrodysplasia 
ossificans progressiva have been recognised as possible mis-
diagnoses [5, 37, 38]. 
Fresh insights into possible treatment failures were noted 
by Hefter et al. who analysed how disease progression dur-
ing treatment may influence the outcome. They included 
74 patients with a mean time of treatment of 9.9 years. Mean 
improvement of CD reported by the patients and scored by 
the physician was about 50%. The frequency of all symptoms 
(abnormal head position, reduced mobility, head tremor, 
muscle tension, pain) increased with duration of therapy. 
The longer the gap between the onset of symptoms and the 
onset of BoNT therapy, the poorer the long-term outcome, 
independent of the duration of BoNT treatment [39]. An-
other group noted in a cohort of 149 patients followed for 
14 years the spread of dystonia from isolated to more complex 
forms in 23.5% cases [36]. In a series of studies, Marciniec 
et al. reported that compared to moderate/good treatment 
satisfaction, CD patients with none/low BoNT efficacy had 
increased incidence of cervical pain, enhanced mean VAS 
score for pain, and higher coexistence of oromandibular 
dystonia (spread of dystonia). In addition, worse treat-
ment satisfaction correlated with enhanced scores of Tsui, 
TWSTRS, as well as TWSTRS subscales: severity, disability 
and pain [40, 41]. Neutralising antibodies may still be a real 
problem: Hefter et al. noted them in 16.2% of patients in 
long-term treatment. This was correlated with higher doses 
of BoNT used, longer treatment, and higher scores in CD 
severity scales [39].
We must systematically assess our patients at subsequent 
sessions, looking for new patterns evolving or new muscles 
involved, and adjust our injection regimens accordingly.
In a case of treatment failure at the onset of treatment, or 
if there is a loss of initial good effect, other treatment options 
such as DBS should be considered. If the patient did not re-
spond from the very beginning, we recommend an algorithm 
and consultation at a secondary or tertiary movement disorder 
centre experienced in BoNT therapy (Fig. 2).
Duration of symptom relief between 
injections
It is a well-established rule to treat patients no more 
frequently than every 12 weeks. So-called booster injections (it 
was a common practice in the early years to inject patients with 
an additional dose after several weeks) have been identified as 
the chief culprit of antibody formation and secondary non-
responsiveness. Many patients have a shorter beneficial period 
(mean 10.5 weeks in 88% of patients) [42], and therefore physi-
cians are tempted to inject earlier. They may be encouraged by no 
reports on antibody formulation after new BoNT/A preparation 
without complexing proteins (INCO-BoNT/A) [43]. Neverthe-
less, despite the potential risk of antibody formation, it may also 
result in dose accumulation and adverse effects such as dysphagia 
or muscle weakness. Walter et al., in a long-term treatment [9.8 
± 6.2 years (range, 0.5–30 years; adherence, 70.6% with 31.2 
± 22.5 (3–112) treatment cycles], showed that independent risk 
factors for neutralising antibodies were high BoNT dose per treat-
ment, switching between onabotulinumtoxinA and other BoNT 
formulations (except for switching to incobotulinumtoxinA), 
and treatment of neck muscles. They did not find antibodies 
in a group of 49 patients treated with incobotulinumtoxinA for 
up to 14 years. The authors recommended the use of the lowest 
possible dose for CD patients and avoiding unnecessary switch-
ing between formulations. The mean cumulative dose over time 
was a risk factor for antibodies formulation after ABO-, but not 
ONA- or INCO-BoNT/A [19]. This means also that we should 
avoid shortening the time between injections. On the other hand, 
ABO-BoNT/A injections for CD or spastic paresis (500-1,000 U) 
had prolonged efficacy, and 72.6%, 77% and 81.5% of patients 
did not require injections at week 12 in three consecutive cycles. 
Moreover, 22.6%, 26.5% and 22.8% respectively did not require 
injections even after 24 weeks [44]. In real life, however, Supnet et 
al. reported that only 47% received injections every 12 weeks [36]. 
Alternative treatments in refractory cases
Pallidal DBS seems to be the most effective alternative 
treatment option for refractory patients [45, 46]. The authors 
of a systematic review of 18 studies concluded that both surgi-
cal peripheral denervation and DBS are associated with a sig-
nificant reduction in absolute TWSTRS total score, with no 
significant difference in the magnitude of reduction observed 
between the two treatments [47]. A small series of patients 
confirmed the long-term treatment effects (10–12.8 years): CD 
scores improved by 53% (total TWSTRS); by 54.1% (severity 
score); and by 70.1% (disability score). Pain did not improve 
significantly. Improvement was stable over time. Patients with 
a tonic pattern of CD responded less to DBS than patients with 
a phasic pattern, and the effects were unrelated to aetiology [48]. 
According to analysis by the Cochrane group, severity of symp-
toms of CD after DBS GPi has been reduced across studies, 
but quality of life and safety concerns are still uncertain [2]. 
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Treatment failure in three consecutive sessions
Reconsider the diagnosis    
(symptomatic dystonia, pseudodystonia).
Reconsider the proper dystonia pattern.
Use EMG/US guidance if not used before.
Increase the dose per muscle and total dose.
Consider non-motor symptoms 
and expectations
Secondary or tertiary consultation
at highly experienced BoNT therapy centre
Consider DBS GPi
Diagnosis of cervical dystonia
Satisfactory treatment in following sessions
Decreased or lack of improvement
Consider dystonia overflow, change of
pattern, change of muscles involved
Consider secondary non-responsiveness 
due to neutralising antibodies formation.
Frontal muscle test suggested.
BoNT/B trial
Secondary or tertiary consultation
at highly experienced BoNT therapy centre
Consider DBS GPi
Treatment with BoNT
Figure 2. Algorithm for identification of possible treatment failures when starting and continuing treatment of patients with cervical dystonia
The unmet need seems to be a lack of clear protocols (as in 
Parkinson’s Disease) regarding patient selection.
The next interventional procedure is selective muscle 
denervation. Wang et al. recently published a large series of 
648 patients operated on successfully between 1995 and 2013, 
with a significant improvement observed between preoperative 
and postoperative TWSTRS evaluation (73.5 ± 11.9 %) [49]. 
These results are in concordance with the earlier (between 
1988 and 1996) study by the Mayo Clinic Group with a long-
term follow up of a mean 3.4 years in 130 patients. The original 
level of moderate-to-excellent improvement in head position 
and pain was retained in at least 71 patients (70%) [50]. Both 
these studies were retrospective. In the era of DBS, further 
prospective studies are required to confirm these results in 
randomised and blinded studies.
Conclusions
Botulinum neurotoxins offer effective treatment of CD, but 
challenges remain. The Col-Cap concept seems convincing. 
However, it is not widely used, nor are US/EMG guided 
injections. One possible obstacle seems to be the lack of 
well-documented studies showing Col-Cap superiority over 
the traditional approach. The lack of specific rating scales is 
probably one of the reasons. 
Treatment protocols should also take into consideration 
non-motor symptoms (especially neuropsychiatric and senso-
ry ones like pain) and the real expectations of patients. Also, 
unresolved issues include the proper dose per muscle/session 
and the correct treatment interval so as to avoid pseudo- or 
secondary failures (too small or too high doses, potentially 
resulting in lack of efficacy in the former or antibody forma-
tion in the latter). Alternative treatment options such as DBS 
GPi should be offered after careful selection of refractory 
patients, but there is as yet no consensus on selection and 
outcome protocols. Further studies are needed to answer all 
these unresolved questions.
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